B+
Bull case
20%
Probability
Target price
$15.50
+64.9% vs current
KODK
Eastman KodakDNYSE / Technology Hardware & Equipment
Last Price
At close
2026-06-18
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$12.50
+33.0% vs current
B-
Bear case
35%
Probability
Target price
$10.00
+6.4% vs current
AI sentiment snapshot
Latest data as of 2026-05-09
Recent news sentiment (30D)
+4.4
Mixed
Company
-
Unavailable
Macro
+5.2
Positive
Pulse
-3.7
Mixed
Sentiment proxy
+79.1
Score
AI commentary
News flow is active because of the May 7 earnings release, but the tone is mixed rather than constructive. The most objective near-term signal is the price response: KODK fell about 19% from $14.15 on May 7 to $11.41 on May 8, indicating the market focused more on cash usage, debt paydown, and capital-structure complexity than on the third straight quarter of operating improvement. Trusted post-print analyst revision evidence was not available in the checked materials, so this remains a cautious monitoring memo rather than a conviction upgrade.
RankAlpha Sentiment Codex - 2026-05-09
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-15catalystPost-earnings digestion is now centered on whether operating improvement can outweigh the balance-sheet overhangHigh impact
Kodak's May 7 first-quarter release showed revenue up 7% to $265 million, gross profit up 24% to $57 million, and Operational EBITDA up to $15 million, but GAAP net loss widened to $16 million and quarter-end cash fell to $299 million. The stock then fell from $14.15 on May 7 to $11.41 on May 8, suggesting investors are discounting the results through liquidity and financing risk rather than operating progress alone [#8-K-2026-05-07] [#10-Q-2026-05-07].
2026-06-01eventJune 1 debt-paydown and preferred-structure follow-through remain the clearest near-term hard catalystHigh impact
The March 31, 2026 10-Q says Kodak prepaid $50 million of term loans on March 13, 2026 and must prepay another $50 million by June 1, 2026, while also carrying 6.0% Series B preferred stock with tranche-based mandatory-conversion thresholds starting at a $14.50 closing-price test. That keeps liquidity, covenant compliance, and capital-structure execution in focus even after the earnings print [#10-Q-2026-05-07] [#10-K-2026-03-12].
2026-09-30catalystPharmaceuticals and AM&C expansion still offer upside optionality, but commercialization proof is still neededHigh impact
Kodak's January 26 investor release said it expanded its pharmaceuticals portfolio with four regulated products that were immediately available for order and noted the Rochester cGMP facility plus an ongoing ISO 13485 application. That supports a real growth-option narrative inside AM&C, but the Q1 release still shows only modest AM&C revenue growth, so investors likely need tangible scale before assigning meaningful value [#IR-2026-01-26] [#8-K-2026-05-07].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-09 • Updated nightlySource: Internal modelMethodology